Results 241 to 250 of about 29,485 (291)
The promise of bispecific antibodies: Clinical applications and challenges
Cancer Treatment Reviews, 2021 The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies.
Sun Min Lim, Kyoung-Ho Pyo, Ross A Soo
exaly +2 more sources
Bispecific antibodies: design, therapy, perspectives
Drug Design, Development and Therapy, 2018 Sergey E Sedykh, Victor V Prinz, Valentina N Buneva, Georgy A Nevinsky Laboratory of Repair Enzymes, Siberian Branch of Russian Academy of Sciences Institute of Chemical Biology and Fundamental Medicine, Novosibirsk State University, Novosibirsk, Russia
Sergey E Sedykh +2 more
exaly +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Bispecific Antibodies for the Treatment of Neuroblastoma
SSRN Electronic Journal, 2022Bispecific antibodies (BsAb) are a new generation of antibody-based therapy, conveying artificial specificity to polyclonal T cells or radiohaptens. These drugs have been successfully implemented to cure hematologic malignancies and are under clinical investigation for solid tumors including HRNB.
Madelyn, Espinosa-Cotton +1 more
openaire +2 more sources
Engineering bispecific antibodies
Current Opinion in Biotechnology, 1993Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
P, Holliger, G, Winter
openaire +2 more sources
Bispecific Antibodies in Lymphoma
International Reviews of Immunology, 1993info:eu-repo/semantics ...
Brissinck, J +4 more
openaire +3 more sources
A revival of bispecific antibodies
Trends in Biotechnology, 2004Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Peter, Kufer +2 more
openaire +2 more sources
Production of Bispecific Antibodies
Current Protocols in Immunology, 1995AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
David M, Segal, Bert J E G, Bast
openaire +2 more sources
Immunotherapeutic perspective for bispecific antibodies
Immunology Today, 2000Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
A B, van Spriel +2 more
openaire +2 more sources
Bispecific antibodies for the treatment of hemophilia A
Expert Opinion on Biological Therapy, 2021Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as indicated patients, ITI, application to PUPs, hemostatic treatment including surgeries, and emicizumab-related morbidity remain to be ...
openaire +2 more sources
Catumaxomab: A bispecific trifunctional antibody
Drugs of Today, 2009The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
M, Sebastian +3 more
openaire +2 more sources